Amgen’s shares down after obesity drug fails to meet expectations
MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide’s latest trial produced a body weight reduction of up to 20%. The results disappointed Wall Street, which had expected results of up Read More →
Strong quarter from Inogen helps stock climb double digits
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Updated: Oracle sues Procore over payments trade secrets
Software giant Oracle is suing Procore Technologies, alleging that the Carpinteria-based software firm used thousands of stolen trade secrets to enrich its business. Procore, a leading construction industry software company and Oracle rival, denied the allegations in an Oct. 31 statement. “We believe the claims are meritless and we intend to vigorously defend ourselves,” Procore said in its statement. Procore’s shares have largely been unaffected by the filing; Read More →
The Trade Desk shares gain back 12% loss in week after earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind keeps hitting higher revenues
Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, announced that revenue for the quarter ended Sept. 30 hit $70.1 million, up from $51.2 Read More →
Olaplex’s struggles continue as earnings miss estimates
Montecito-based Olaplex missed analyst expectations in both revenue and net income when it announced its earnings for the third quarter of 2024. Announced Nov. 7, Olaplex noted that sales decreased 3.6% to $119.1 million in the third quarter of 2024.As a result, net income decreased 27.3% to $14.7 million and adjusted net income decreased 13.8% Read More →
Procore cuts down on losses, keeps growing sales
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
